Table 1.
Patient Background Characteristics
| Characteristics | Patients (N = 300) |
|---|---|
| Age (y) | |
| Mean (range) | 67.1 (28–91) |
| Sex | |
| Male/female | 228/72 |
| Smoking history | |
| Never/former/current/other | 39/199/53/9 |
| Smoking index (N = 253) | |
| Mean (range) | 965.7 (9–3300) |
| Performance status | |
| 0/1/2/3/4 | 88/161/38/11/2 |
| Histology | |
| Squamous/nonsquamous | 79/221 |
| EGFR mutation | |
| Positive/negative/unknown | 22/250/28 |
| ALK fusion | |
| Positive/negative/unknown | 2/257/41 |
| PD-L1 TPS | |
| 1%–49%/≤50%/unknown | 57/242/1 |
| Stage | |
| II–III/IV/recurrence | 44/191/65 |
| Previous chemotherapy | |
| ≤1 line/≤2 lines/unknown | 244/53/3 |
| Liver metastasis | |
| None/metastasis | 277/23 |
| Brain metastasis | |
| None/metastasis | 248/52 |
| Bone metastasis | |
| None/metastasis | 226/74 |
| Malignant pleural effusion | |
| None/metastasis | 286/14 |
| Steroid usage | |
| None/use/unknown | 286/11/3 |
| Radiation (before ICI) | |
| No/yes | 209/91 |
| Surgery (before ICI) | |
| No/yes | 243/57 |
| Body mass index (kg/m2) | |
| Mean (range) | 21.7 (14.3–40.0) |
ICI, immune checkpoint inhibitor; PD-L1 TPS, programmed cell death-ligand 1 tumor proportion score.